No one would describe 2020 as normal. The coronavirus disrupted travel, employment and livelihoods. It pushed countries into lockdown, forcing people to change how they lived. And it infected millions of people, resulting in many getting severely ill and dying. The high number of deaths in 2020 was completely abnormal.
“Excess mortality” is how this abnormality is measured. It’s the number of deaths – from all causes – that occur during a crisis that’s beyond what would be expected in typical times. When looking across a sample of 79 high-, middle- and low-income countries, overall there were 3.7 million more deaths in 2020 compared with the average for 2015-19 – an excess of 13%.
This figure reflects not only official COVID deaths, but those caused by the virus yet not recorded as such. It also includes deaths that might have been prevented if the pandemic hadn’t happened – those caused by cancers or strokes going untreated due to healthcare systems being overwhelmed, or by the effects of lockdowns and rising poverty.
What’s really striking is that these deaths have not been spread evenly across the world. COVID deaths have varied greatly across countries, and the geography of excess mortality in 2020 was also significantly uneven. For instance, while excess deaths in Mexico and Nicaragua in 2020 were 50% above the 2015-19 average, Mongolia and Australia recorded negative excess mortality. As I found in my recent research, a number of factors can explain this.
Table of Contents
To handle the COVID health emergency well, countries needed to be prepared. Those entering the pandemic with insufficiently funded healthcare systems and limited resources were more likely to be overwhelmed and have high levels of excess death.
Among the countries examined, Azerbaijan spent the lowest proportion of its GDP on health and had the fifth-highest excess mortality (32%). South Africa had among the lowest number of doctors – 90 per 100,000 people – and quite high excess mortality, at 14%. And Paraguay had just 83 medical beds per 100,000 residents and 12% excess mortality. Healthcare funding was among the most crucial factors for keeping deaths down.
Good primary healthcare – which allowed countries to monitor patients with mild symptoms without having to send them to hospital – was also crucial. Limiting hospital admissions reduces the risk of COVID spreading and allows hospital staff to focus on treating those severely ill with COVID and other diseases.
Universal access to healthcare was another important factor. In countries where barriers prevent poorer people from accessing care – for instance, where the state has been “hollowed out”, with state-provided healthcare being supplanted by privatisation coupled with low health-insurance coverage – high excess mortality was more likely.
Egypt and Azerbaijan, with their heavily privatised healthcare systems, both had plenty of excess deaths. In Ecuador and El Salvador, less than a quarter of people are covered by health insurance. Excess mortality in these countries was 49% and 21% respectively.
Contrary to what you would think, countries with the longest and most stringent lockdowns were likely to have higher rather than lower excess mortality. Governments that used them did so because they failed to act in time. They implemented delayed lockdowns across their entire countries, underestimating the virus and prioritising economic order.
Chile, El Salvador and Peru had the most stringent lockdowns, and all recorded a rate of excess mortality that was 20% or higher. In contrast, lockdown stringency in Norway, Iceland and Finland was low. Their excess deaths didn’t exceed 3%.
Having a strong test, trace and isolate system was strongly associated with fewer deaths. For example, Taiwan recorded just 1.6% excess deaths and 0.03 COVID deaths per 100,000 people during 2020 and had one of the world’s most efficient test-and-trace systems.
Location, location, location
Geographically isolated island countries, such as New Zealand and Iceland, were more likely to record low excess mortality. They were better placed to control their borders and detect people infected with COVID on arrival.
Several Asian countries tended to have strong test-and-trace capacity, and this frequently resulted in lower excess mortality (China and Japan being examples, alongside Taiwan). These countries managed to contain the pandemic in 2020 by conducting comprehensive contact tracing for all COVID cases.
In contrast, Central and South American countries tended to have weak test-and-trace capacity. Four of the five worst hit countries were in Latin America (Mexico, Nicaragua, Ecuador and Bolivia). Countries with the longest periods of stay-at-home orders also tended to be in Central and South America.
As you might expect, having many COVID deaths was linked to increased excess mortality. However, collectively across the 79 countries examined, excess deaths in 2020 were more than double the total officially registered as COVID fatalities (3.7 million to 1.5 million).
This underlines that COVID deaths are likely to have been significantly under-reported during the year. For instance, COVID deaths in Poland (28,550) accounted only for 34% of the country’s excess fatalities (83,530) in 2020. Similarly, the US-registered 351,000 COVID fatalities in 2020, but 625,000 excess deaths.
How to do better next time
During the first year of the pandemic, most governments ended up implementing punishing measures to try to control the virus, such as lengthy lockdowns and personal restrictions.
Governments could achieve better health outcomes in future by making sure that their responses are more timely, kicking in before the infection rate escalates. They could also make disease control more effective by improving test-and-trace capacity and boosting the preparedness of health systems, by providing sufficient funding and making services accessible to the whole population.
Even now, vaccines cannot be relied on as the sole solution to the pandemic. To keep excess deaths down, much more needs to be done to stop healthcare systems from being overwhelmed by generously supporting them and enhancing test-and-trace systems.
Nikolaos Kapitsinis does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.